Vetoquinol H1 2026: Why a Steady 5% Grower Trades at a Discount to Its Own Margins

Vetoquinol is not one of the household names in veterinary pharmaceuticals. If you've never heard of it, you're in good company — U.S. investors usually think of Zoetis when the topic comes up. But this French company, with a $900 million market cap, just reported first-half 2026 results that reveal something worth paying attention to: a profitable, cash-generating animal-health business whose valuation looks cheap next to the industry's largest players, and not for any obvious reason.

The results, released on September 10, show a company growing at a modest but solid pace while expanding the profit it keeps. Total sales for the first six months of 2026 reached €259 million, up 0.7% on a reported basis and 3.4% at constant exchange rates. The underlying business growth — stripping out foreign-exchange headwinds and a deliberate product-simplification program — was 4.8%. That's not headline-grabbing. It's also not the kind of number that usually commands a premium.

But the profit side tells a different story. Net income for the group came in at €30.5 million, up 22% year over year, lifting the net margin to 11.8% of sales from 10.9% in the comparable 2025 period. Operating profit before amortization of acquired intangibles was €45 million, or 17.3% of revenue — essentially flat from the full-year 2025 EBIT margin of 17.4%, which suggests the first half is in line with, or slightly ahead of, the full-year pace. Cash flow generation for the period reached €59 million.

What does that look like relative to the companies investors usually buy in this space?

The comparison set

The animal-health sector is dominated by names like Zoetis (NYSE: ZTS, $30 billion market cap) and Elanco (NYSE: ELAN, $11.4 billion market cap). Both are publicly traded in the U.S. and generate tens of billions in annual revenue. Vetoquinol is a different animal entirely — smaller, French-listed, with about €526 million in annual sales (2025 full year). But it operates in the same industry, serves the same customers, and faces the same secular tailwinds from rising pet ownership and humanization trends that are expected to grow the global companion-animal drug market at 8–12% annually through 2033.

So what separates Vetoquinol's economics from its much larger peers?

Zoetis, by far the biggest player, is an exceptionally efficient business. It trades at a forward P/E of roughly 11x after a brutal 2026 — the stock is down about 50% from its 52-week high — and carries operating margins near 37% and a return on invested capital of 23%. Its gross margins sit around 72%. That's a top-tier operation. But it's also a mature, highly leveraged balance sheet paying out roughly 33% of earnings as dividends, with revenue growth in the single digits (around 1.6% year over year).

Elanco is the other reference point. Revenue growth looks stronger — nearly 12% year over year — but profitability tells a cautionary tale. Operating margins hover around 1.6%, the company posted negative earnings for the trailing twelve months, and return on equity is minus 3%. The stock trades at a negative P/E and a forward multiple of roughly 73x, pricing in a turnaround that hasn't materialized yet.

Vetoquinol sits between them. Its operating margins of 17.3% are far below Zoetis but substantially above Elanco. Its return on equity of roughly 9.8% is positive and steady, and its return on assets of 6.6% suggests capital is being employed productively. Revenue growth of 4.8% sits between Zoetis's stagnation and Elanco's acceleration. The company doesn't have the scale of Zoetis or the growth ambition of Elanco — but it has the profitability to stand on its own.

Where the growth is coming from

About 73% of Vetoquinol's revenue comes from companion animals — dogs and cats — while the remaining 27% is farm animals. Companion-animal sales grew 4.1% at constant exchange rates, consistent with the broader industry trend of pet owners spending more on preventive care and specialty treatments. Farm-animal growth was slower at 1.9%, which makes sense given the cyclical pressure on livestock margins globally.

Geographically, the United States is where things are moving the fastest. U.S. sales rose 13.1% in local currency — more than triple the overall growth rate and the single strongest regional performance. That matters because the U.S. is Vetoquinol's largest market and where the company has been investing to build out its distribution and specialty-pharmacy network over the past several years. Europe grew 3% at constant exchange rates, while the rest of the Americas and Asia-Pacific both declined slightly. The pattern is clear: U.S. growth is carrying the global growth number.

The valuation question

Here's where the story gets interesting. Vetoquinol trades at a trailing P/E of roughly 14x and a price-to-sales ratio near 1.1x based on its $900 million market cap. Compare that with Zoetis at roughly 3.2x sales and a forward P/E of 11x, and Elanco at 2.3x sales with no current earnings multiple.

Vetoquinol is cheaper than both on a sales basis, even though it has the actual profitability that Zoetis enjoys and that Elanco currently lacks. A company growing revenue at 4–5% organically, expanding its net margin from 10.9% to 11.8%, generating €59 million in cash flow on €259 million of revenue, and running a 17.3% operating margin should not trade at less than half the sales multiple of a company growing at 1.6%.

The discount exists, and it's not necessarily an accident. Vetoquinol is a small-cap foreign listing — French shares traded on the Paris exchange, available in the U.S. only through an OTC ticker (VETOF). The liquidity is thinner, the analyst coverage is sparse, and U.S. investors tend to overlook European mid-cap names in favor of domestic large caps. That kind of structural inattention is exactly the condition that creates persistent valuation gaps.

The company also carries a dividend yield of roughly 1.3%, with a history of annual increases over the past decade and a payout ratio that earnings comfortably cover. Cash flow generation of €59 million in the first half — roughly 23% of revenue — leaves room for both dividend growth and potential share buybacks.

What could go wrong

No small international stock is without its blind spots. The product-simplification program that shaved €3 million from reported revenue signals that the company is pruning lower-margin or redundant products — a sensible move for profitability but one that caps short-term top-line growth. The 4.8% underlying growth rate, while steady, may not be fast enough to justify a re-rating toward Zoetis-level multiples in the near term. And Vetoquinol's exposure to Europe and international markets means ongoing currency headwinds can mask the organic trend.

There's also the question of innovation pipeline. Zoetis and Elanco invest billions in R&D and bring blockbusters to market. Vetoquinol's R&D spend is proportionally smaller, and the company has hinted at several new product launches on the horizon without naming them. If those launches don't land or fail to gain traction, the growth story stays modest and the valuation gap may persist.

What it means

Vetoquinol isn't a momentum play or a growth-at-all-costs story. It's a profitable animal-health business that sits in an expanding industry, growing steadily, expanding margins, generating real cash flow, and trading at a valuation that reflects its small-cap international status more than its fundamentals. The 22% increase in net income, the margin expansion from 10.9% to 11.8%, and the 13% U.S. growth rate are all in the same direction.

The factor stack doesn't scream breakout — 4.8% growth and a 14x P/E are neither hot nor extreme. But the company is cheap relative to its own profitability, and the margin trajectory is moving upward, not sideways. In a sector where one player (Zoetis) is being punished for near-term weakness and another (Elanco) is paying premium multiples for unproven growth, Vetoquinol offers something less glamorous but harder to dismiss: steady earnings at a discount.

The tradeoff is that patience is part of the thesis. The valuation gap won't close overnight, and the company will need to keep delivering on margin expansion and U.S. growth to convince the broader market that this isn't just a small European name with no catalyst. If it does, the math starts to work in the investor's favor. If it doesn't, the discount may endure — and that's a risk worth acknowledging before the position is built.